# Radiation/Nuclear Medical Countermeasure (MCM) Product Development Support Services

> **NIH NIH N01** · SRI INTERNATIONAL · 2020 · $480,156

## Abstract

The Department of Health and Human Services has assigned the NIH the responsibility to identify, characterize, and develop new medical countermeasures (MCM) against radiological or nuclear threats. As part of the “NIH Strategic Plan and Research Agenda for Medical Countermeasures against Radiological and Nuclear Threats”, the NIAID awarded the Medical Countermeasures against Radiological Threats: Product Development Support Services contract to provide support services for products that may have the potential to become radiation or nuclear medical countermeasures. This contract is tasked with bringing these potential countermeasures to a point at which they can 1) be approved or licensed by the U.S. Food and Drug Administration (FDA) or 2) transition to the Biomedical Advanced Research and Development Authority (BARDA). When approved, these MCMs could be acquired by the Strategic National Stockpile.

## Key facts

- **NIH application ID:** 10215219
- **Project number:** 272201500013I-P00011-27200007-1
- **Recipient organization:** SRI INTERNATIONAL
- **Principal Investigator:** POLLY CHANG
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $480,156
- **Award type:** —
- **Project period:** 2015-09-01 → 2020-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10215219

## Citation

> US National Institutes of Health, RePORTER application 10215219, Radiation/Nuclear Medical Countermeasure (MCM) Product Development Support Services (272201500013I-P00011-27200007-1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10215219. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*